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Abstract
A	pilot	study	was	conducted	aiming	at	specifying	sultiame's	pharmacokinetic	profile,	
completed by in vitro assays evaluating the intraerythrocytic transfer of sultiame and 
by a pharmacokinetic model assessing its distribution. Single oral doses of sultiame 
(Ospolot®	 50,	 100,	 and	 200	mg)	were	 administered	 in	 open-label	 to	 four	 healthy	
volunteers.	 Serial	 plasma,	whole	 blood,	 and	urine	 samples	were	 collected.	A	 spik-
ing	experiment	was	also	performed	 to	characterize	 sultiame's	exchanges	between	
plasma	and	erythrocytes	in	vitro.	Pharmacokinetic	parameters	were	evaluated	using	
standard	 noncompartmental	 calculations	 and	 nonlinear	 mixed-effect	 modeling.	
The	 plasma	 maximal	 concentrations	 (Cmax)	 showed	 striking	 nonlinear	 disposition	
of	 sultiame,	with	a	10-fold	 increase	while	doses	were	doubled.	Conversely,	whole	
blood Cmax increased less than dose proportionally while staying much higher than in 
plasma.	Quick	uptake	of	sultiame	into	erythrocytes	observed	in	vivo	was	confirmed	
in	vitro,	with	minimal	efflux.	A	two-compartment	model	with	first-order	absorption,	
incorporating	a	saturable	ligand	to	receptor	binding,	described	the	data	remarkably	
well,	 indicating	apparent	plasma	clearance	of	10.0	L/h	(BSV:	29%)	and	distribution	
volume	of	64.8	L;	saturable	uptake	into	an	intracellular	compartment	of	3.3	L	with	a	
maximum	binding	capacity	of	111	mg	accounted	for	nonlinearities	observed	in	plasma	
and	whole	blood	concentrations.	Pharmacokinetic	characteristics	of	sultiame	are	re-
ported,	including	estimates	of	clearance	and	volume	of	distribution	that	were	so	far	
unpublished. The noticeable nonlinearity in sultiame disposition should be taken into 
account for the design of future studies and the interpretation of therapeutic drug 
monitoring results.
K E Y W O R D S
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1  | INTRODUC TION
Sultiame	 (Bayer	 1960,	 MW	 290	 g/mol)1	 is	 a	 cyclic	 sulfonamide,	
whose antiepileptic activity is thought to mainly result from the inhi-
bition	of	various	subtypes	of	carbonic	anhydrase	(CA).2	In	particular,	
the	blockade	of	cytosolic	CA	II	seems	to	produce	a	degree	of	intra-
cellular	acidification	sufficient	to	stabilize	seizure-eliciting	neurons.	
In	addition,	 an	 inhibitory	action	on	 sodium	channels	possibly	 con-
tributes to its antiepileptic efficacy.2
Sultiame is a first choice treatment in some countries for benign 
childhood	epilepsy	with	centrotemporal	spikes,	a	common	nonlesional	
epilepsy syndrome of childhood usually appearing between 4 and 
12	years	of	age	characterized	by	nocturnal	oro-facial	motor	or	sensory	
seizures,	with	or	without	bilateral	propagation.3 The overall prognosis 
is	good,	with	spontaneous	disappearance	of	epilepsy	at	adolescence.	
However,	some	children	may	have	mild	neurocognitive	deficits	some-
times linked to interictal epileptiform discharges on electroenceph-
alogram.	Although	not	 all	 cases	deserve	 a	 treatment,	 patients	with	
more	 frequent	 seizures	 benefit	 from	 a	 course	 of	 antiseizure	 drug.	
Sultiame has been reported to be well tolerated and possibly more 
effective than other antiepileptic drugs commonly used in focal sei-
zures,	such	as	carbamazepine,	gabapentine,	or	levetiracetam.3-5
Despite	a	regular	use	over	decades	by	pediatric	neurologists,	the	
pharmacokinetic	(PK)	profile	of	sultiame	was	only	scarcely	studied	in	
humans.6-9	Linear	disposition	 is	assumed	by	the	manufacturer,	with	
a	half-life	described	to	lie	“between	2	and	16	hours”,	while	no	values	
have	been	published	 for	 bioavailability	 (F),	 apparent	 volume	of	 dis-
tribution	 (V/F),	 and	apparent	clearance	 (CL/F).	Plasma-free	 fraction	
amounts	to	71%.	Plasma	levels	are	said	to	display	a	significant	degree	
of	 between-	 and	within-individual	 variability,	 even	 at	 steady	 state.	
The	manufacturer	mentions	a	mixed	elimination	by	metabolism	(hy-
droxylation)	and	 renal	excretion,	 the	 latter	concerning	30%-60%	of	
an ingested dose. Two metabolites of sultiame have been identified in 
urines,	the	main	one	being	hydroxy-sultiame	(an	inactive	compound).8
Our	primary	aim	was	to	assess	sultiame's	PK	parameters,	in	order	
to	better	characterize	its	concentration-time	profile.	Preliminary	in-
vestigations	of	the	stability	of	blood	samples	for	PK	measurement	
indicated a marked uptake into erythrocytes that we possibly at-
tributed	 to	 sultiame's	 affinity	 for	 CA	 abundant	 in	 erythrocytes.10 
A	 secondary	 aim	 was	 thus	 defined	 to	 characterize	 sultiame's	 ex-
changes between plasma and erythrocytes through an in vitro spik-
ing	experiment.
2  | MATERIAL AND METHODS
2.1 | Subjects
Eligible	subjects	for	the	clinical	study	were	healthy	adult	male	volun-
teers	aged	18-45	years,	with	a	body	weight	ranging	between	55	and	
95	kg	and	a	body	mass	index	of	18-29	kg/m2. Subjects with a history 
or evidence of clinically significant diseases or interfering conditions 
were	 excluded.	 Other	 exclusion	 criteria	 included:	 history	 of	 any	
clinically significant laboratory value including serology for hepatitis 
and	HIV,	relevant	alcohol	or	drug	abuse,	recent	acute	illness,	or	use	
of any medication the week prior to study.
Single	oral	doses	of	50,	100,	and	200	mg	of	sultiame	(Ospolot®,	
immediate-release	 coated	 tablets)	 were	 administered	 in	 fasting	
conditions,	in	open-label,	during	periods	1,	2,	and	3,	respectively,	
at	 4-6	weeks	 interval.	On	 each	 period,	 serial	 plasma	 and	whole	
blood	 samples	were	collected	predose,	 then	at	15,	30	min,	1,	2,	
3,	 4,	 5,	 6,	 8,	 10,	 24,	 48,	 72	 168,	 336,	 and	 504	 hours	 postdose.	
Plasma	and	whole	blood	samples	were	stored	at	−	80°C	until	anal-
ysis.	Hematocrit	was	measured	using	a	microhematocrit	centrifuge	
machine	 (Haematokrit	 200®,	 Hettich	 AG,	 Bäch,	 Switzerland)	 on	
each	occasion	to	calculate	intraerythrocytic	concentrations.	Urine	
PK	samples	were	collected	in	6	fractions,	before	dosing,	from	0-2,	
2-4,	4-8,	8-10,	and	10-24	hours	postdose.	Urine	pH	was	measured	
on each fraction.
The study protocol had been submitted to and approved by the 
competent	research	ethics	committee	(CER-VD	Nr	2017-02005)	and	
regulatory	authority	(Swissmedic	Nr	2017DR1188;	Clinicaltrials.gov	
identifier:	NCT03400189).
2.2 | Analytical method
The	 quantification	 of	 sultiame	 in	whole	 blood,	 plasma,	 and	 urine	
was	 performed	 using	 a	 high-performance	 liquid	 chromatography	
coupled	 to	 tandem	triple	quadrupole	mass	spectrometry	 (LC-MS/
MS)	method	developed	and	validated	purposely	for	the	trial.	Briefly,	
300	µL	of	methanol	 (MeOH)	containing	 the	 internal	 standard	 (IS)	
sultiame-D4	 (Toronto	Research	Chemicals,	Canada)	was	added	 to	
100	µL	of	 human	plasma,	 hemolyzed	whole	blood,	 or	 hemolyzed	
red	blood	cells,	for	protein	precipitation.	Urine	samples	were	pro-
cessed	similarly.	After	vortex,	sonication	for	30	seconds,	and	cen-
trifugation	steps,	250	µL	of	supernatant	was	transferred	into	a	glass	
vial	with	insert,	followed	by	dilution	with	250	µL	of	pure	water	and	
a	 final	vortex	step,	prior	 to	LC-MS/MS	analysis.	Chromatographic	
analyses	were	 carried	 out	 on	 a	 XSelect	HSS	 T3	 column	 (Waters,	
Milford,	MA,	USA)	using	a	water-acetonitrile	gradient	over	5	min-
utes.	Detection	was	performed	with	a	triple	quadrupole	mass	spec-
trometer	(TSQ	Quantum	Ultra,	ThermoFisher	Scientific,	Waltham,	
MA,	USA)	using	the	m/z	transitions	289.0	→	225.1	for	sultiame,	and	
293.0	→	229.1	for	sultiame-D4.	Lower	limits	of	detection	and	quan-
tification	of	the	method	were	0.001	and	0.01	µg/mL,	respectively,	
with	a	dynamic	range	extending	up	to	50	µg/mL.	No	qualitative	ma-
trix	effect	was	observed	at	sultiame	retention	time.	Deviations	from	
nominal	concentration	(inaccuracy)	of	internal	QCs	were	comprised	
within	−	1.9	to	+	11.7%	over	the	calibration	range.	The	developed	
assay	has	been	applied	 for	 the	 analyses	of	Certified	External	QC	
samples of sultiame in plasma (ClinChek®	N°	14,082	 and	RECIPE	
Chemicals,	Munich,	 Germany)	with	 deviations	 from	 nominal	 con-
centrations	comprised	between	−	4.4	to	+	3.4%,	demonstrating	the	
excellent	accuracy	of	 the	developed	method.	Metabolites,	whose	
chemical	structure	is	still	elusive,	were	not	determined.
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2.3 | Pharmacokinetic parameters
Erythrocytic	concentrations	(Cery)	were	deduced	from	whole	blood	
and plasma measurements as:
where	Ht	is	the	hematocrit	of	the	sample.11
2.3.1 | Noncompartmental analysis
Plasma,	whole	blood,	and	urine	sultiame	PK	parameters	were	 first	
computed for each volunteer using standard noncompartmental cal-
culations with Stata®	(version	13,	StataCorp.	2013,	Stata	Statistical	
Software,	College	Station	TX,	USA).
The	 area	 under	 the	 curve	 for	 a	 single	 dose	 (AUC0-inf)	was	 cal-
culated	using	the	log	trapezoidal	rule	with	extrapolation	to	infinity.	
The terminal rate constant (휆z)	was	derived	from	a	two-exponential	
model	curve.	CL/F	was	calculated	as	the	dose	divided	by	AUC0-inf,	
the	half-life	(t1/2)	as	ln(2)/휆z,	and	V/F	as	(CL/F)/휆z.
2.3.2 | Compartmental analysis
A	 population	 PK	 analysis	 was	 also	 performed	 using	 a	 nonlinear	
mixed-effect	 modeling	 approach	 (NONMEM	 version	 7.4,	 ICON	
Development	 Solutions,	 Hanover	 MD,	 USA).	 Based	 on	 graphical	
exploration	 and	 in	 vitro	 experiments,	 a	 two-compartment	 model	
with	 first-order	 absorption	 incorporating	 a	 saturable	 ligand	 to	 re-
ceptor	binding	was	devised,	as	illustrated	in	Figure	1,	to	account	for	
sultiame's	affinity	for	CA	abundant	in	erythrocytes.	The	model	was	
expressed	in	terms	of	differential	equations	and	first-order	rate	con-
stants of absorption (ka),	elimination	(ke),	association	with	(kon)	and	
dissociation from (koff)	receptors,	maximal	binding	capacity	(Btot),	ap-
parent	central	volume	of	distribution	(Vc/F),	and	erythrocytes’	vol-
ume	of	distribution	(Very).	Note	that	Very actually encompasses the 
volume	of	 all	 types	of	 cells	 containing	 receptors,	 assumed	 to	 tally	
with	the	sampled	erythrocytes.	Plasma	protein	binding	was	assumed	
constant over the whole range of observed concentrations. Renal 
extraction	fraction	(Qren)	was	added	to	characterize	urine	excretion	
with	an	additional	compartment	for	urine	data.	Values	of	kon and koff 
characterized	in	vitro	at	different	temperatures	were	used	as	initial	
estimates and the value of kon	to	2018	µM
−1 h−1	at	37°C	fixed	in	the	
in	vivo	model.	F	was	not	evaluated,	making	the	model	estimate	ap-
parent	values	for	Vc/F	and	CL/F.	The	first-order	elimination	rate	con-
stant from the central compartment was calculated as ke	=	(CL/F)/
(Vc/F).	The	first	value	below	the	LLOQ	was	equaled	to	LLOQ/2	and	
subsequent	nonquantifiable	values	were	discarded	(M6	method).12 
Details	concerning	differential	equations	and	model	building	steps	
and adjustment are available in Supplemental material.
A	 stepwise	 procedure	was	 used	 to	 identify	 the	model	 that	 best	
fitted	the	data,	comparing	two-,	three-,	and	four-compartmental	mod-
els (peripheral or separate intracellular compartments for free and 
bound	 sultiame),	 and	 other	 nonlinear	 models	 (Bmax	 sigmoid	 model).	
Exponential	errors	were	used	for	the	description	of	between-subject	
variability	(BSV)	of	PK	parameters.	Proportional,	additive,	and	mixed	
error models were compared to describe the residual variability. The 
stability and internal validity of the final model were assessed by means 
of	standard	procedures,	detailed	in	Supplemental	material.	Covariates	
were	not	analyzed	due	to	the	limited	number	of	subjects	included.
2.4 | Safety assessments
All	 adverse	events	were	 recorded	with	an	evaluation	of	 their	 se-
verity	and	imputability	to	the	study	drug.	Each	volunteer	received	
a	 full	 medical	 examination	 at	 screening	 and	 at	 the	 end	 of	 the	
study.	Visual	analogue	scales	(VAS)	on	paper	support	recorded	the	
Cery=
Cwhole blood−Cplasma ⋅
(
1−Ht
)
Ht
F I G U R E  1  Compartmental	model	accounting	for	nonlinearity	of	distribution.	Aa,	amount	of	sultiame	at	the	absorption	site;	Ap,	amount	
of	sultiame	in	plasma	and	central	compartment;	Vc,	central	volume	of	distribution;	Aery,	amount	of	sultiame	in	the	cells,	assumed	to	be	bound	
to	receptors;	Very,	cellular	volume	of	distribution;	ka,	absorption	rate	constant;	ke,	elimination	rate	constant;	kon,	constant	of	association	onto	
receptors binding sites; koff,	constant	of	dissociation	from	the	binding	site;	Bbound,	amount	of	occupied	receptors,	assumed	equal	to	Aery;	Bfree,	
amount	of	free	binding	sites;	Btot,	sultiame	maximal	binding	capacity	(mg);	Qren,	renal	fraction	of	the	elimination	rate;	Foral,	oral	bioavailability,	
assumed	equal	to	1
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intensity	of	12	potential	symptoms	(abdominal	pain,	appetite,	nau-
sea,	taste	of	sparkling	water,	fatigue,	headache,	dyspnea,	dizziness,	
paresthesia,	difficulty	in	concentration,	irritability,	and	depression)	
predrug	 (0	hour)	 at	0.5,	1,	2,	4,	6,	8,	10,	 and	24	hours	postdose.	
Vital	 signs	 (supine	blood	pressure,	 heart	 rate,	 body	 temperature,	
and	respiratory	frequency)	were	measured	predose	and	at	1,	2,	4,	6,	
8,	10,	and	24	hours	postdose.	Laboratory	parameters,	drug	screen,	
and urinalysis were performed at screening and at study end.
2.5 | In vitro assays
A	spiking	experiment	was	performed	to	better	characterize	sultiame	
exchanges	 between	 plasma	 and	 erythrocytes.	 The	 influx	 into	 cells	
was	investigated	through	spiking	fresh	human	whole	blood	on	EDTA	
at	different	target	concentrations	(1,	5,	10,	20,	40,	and	80	mg/L)	and	
different	temperatures	(4,	21,	and	37°C),	followed	by	sampling	at	0,	2,	
4,	6,	8,	10,	15,	30,	60,	120,	and	180	min.	The	efflux	was	investigated	
through incubating whole blood for 1 h at 2 concentrations (10 and 
40	mg/L)	at	37°C,	centrifugating	and	briefly	washing	the	erythrocytes	
with	NaCl	0.9%,	and	letting	them	equilibrate	with	fresh	plasma	while	
drawing	samples	at	0,	2,	4,	6,	8,	10,	15,	30,	60,	120,	180	minutes,	and	
24 hours.
In	addition,	competition	studies	were	performed	with	two	other	
antiepileptic	 agents	 known	 for	 their	 affinity	 for	 CA	 (zonisamide	
and	 topiramate),	 added	 at	 equimolar	 concentration	 to	 20	 mg/L	
of	 sultiame.	 Similar	 ranges	of	 inhibition	 constants	 for	CA	 II	were	
reported in the literature for these three substances.13 Samples 
F I G U R E  2  Log-transformed	plasma	
and erythrocyte concentrations of 
sultiame:	predicted	concentration-time	
profiles	(continuous	lines)	and	geometric	
mean and standard errors of observations 
in	erythrocytes	(A)	and	plasma	(B),	after	
administration of single doses of 50 mg 
(circles),	100	mg	(diamonds),	and	200	mg	
(triangles).	Insets	zoom	on	the	first	
24 hours after drug intake
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(1	mL)	were	drawn	before	and	at	2,	4,	6,	8,	10,	15,	20,	30,	45,	60,	
and	120	min	after	addition	of	the	competitor.	Sultiame,	zonisamide,	
and	 topiramate	 concentrations	 were	 then	 analyzed.	 All	 samples	
were centrifuged at 18 620 g	for	1	minutes	at	4°C.	Plasma,	erythro-
cyte,	and	urine	fractions	were	stored	separately	at	−	80°C	prior	to	
analysis	for	a	maximum	of	9	months.	For	analysis,	plasma	and	he-
molyzed	erythrocytes	samples	were	subjected	to	protein	precipita-
tion	with	MeOH	containing	the	internal-standard	sultiame	D4	and	
quantified	 with	 the	 previously	 described	 HPLC-MS/MS	 method,	
using	matrix-matched	calibration	and	quality	controls.	The	sultiame	
concentrations determined in erythrocytes were corrected for the 
10%	 interstitial	 plasma	 remnant	 in	 the	erythrocyte	 fraction	after	
centrifugation.14
3  | RESULTS
3.1 | Subjects
Four	male	subjects	completed	 this	 study	part	without	any	drop-
out.	Age	 (mean	±	SD)	was	25	±	3	 years	 (range	22-28	years)	 and	
weight	69	±	2	kg	 (range	65-71	kg)	at	 inclusion.	Safety	and	toler-
ability assessments revealed limited impact on gastrointestinal 
and	central	nervous	system	tolerance	using	VAS.	Fatigue	was	the	
symptom	most	frequently	reported.	Transient	facial	and	limb	par-
esthesia were reported by three subjects after intake of the high-
est	 dose	 of	 200	mg.	 No	 severe	 or	 serious	 adverse	 events	were	
reported.
3.2 | Noncompartmental 
pharmacokinetic parameters
Average	 sultiame	 plasma	 and	 whole	 blood	 concentrations	 after	
single	oral	doses	of	50,	100,	and	200	mg,	administered	at	4	weeks	
intervals,	are	represented	in	Figure	2.	The	plasma	maximal	concen-
tration (Cmax)	 revealed	 striking	 nonlinear	 disposition	 of	 sultiame,	
with	10-fold	increases	between	each	dose	levels,	while	doses	only	
doubled.	Conversely,	whole	 blood	Cmax increased less than dose 
proportionally	and	were	much	higher	than	those	in	plasma.	PK	pa-
rameters of sultiame obtained by noncompartmental calculations 
are	reported	 in	Table	1	 for	each	dose.	Nonlinearity	 for	CL/F	and	
area	under	the	curve	(AUC0-inf)	is	salient	between	dose	levels,	sug-
gesting	 a	 saturation	process	 in	 distribution	 in	 erythrocytes.	 Low	
Vc/F	 values	 for	 whole	 blood	 sultiame	 contrast	 with	 high	 values	
for	plasma,	 in	line	with	the	important	intracellular	uptake.	Whole	
blood	AUC0-inf	values	are	much	higher	than	plasma	AUC0-inf values 
and	show	inverse	trends	for	dose	dependency	compared	to	CL/F	
estimates.	A	 fair	 degree	 of	 interindividual	 variability	 is	 observed	
between	subjects.	Nonlinearity	is	noted	as	well	in	the	urinary	re-
covery	of	unchanged	sultiame,	which	increases	about	10-fold	be-
tween	the	50	and	200	mg	doses.	Still	renal	CL	remains	unaffected	
by dose.
3.3 | Compartmental analysis
A	 2-compartment	model	 incorporating	 a	 saturable	 ligand	 to	 re-
ceptor	binding,	completed	with	the	in	vitro	kon and koff values and 
a	compartment	for	urines,	best	described	the	data.	In	addition	to	
CL/F	(ΔOFV	of	−	74),	BSV	on	QRen (ΔOFV	−	21)	was	incorporated	
into the model. Intrapatient residual variability was best described 
using	a	proportional	error	for	plasma,	erythrocytes,	and	urine	val-
ues.	A	relatively	simple	ligand	to	receptor	model	captured	remark-
ably	well	the	nonlinear	kinetics	of	sultiame	across	the	dose	levels,	
assuming a saturable amount of binding sites in erythrocytes and 
possibly other types of cells. There were no indications for using 
more	complicated	models:	for	example,	a	sigmoid	Bmax model did 
not perform better (ΔAIC	+	29);	adding	a	linear	component	to	ac-
count for nonsaturable transfer of sultiame into erythrocytes did 
not provide strong evidence of model improvement (ΔAIC	−	2.5).	
Conversely,	 classical	 linear	models	were	 unable	 to	 describe	 the	
data. The final base population parameters are listed in Table 2 
and the average concentration predictions for each dose level are 
shown	on	Figure	2.	Individual	profiles	of	predicted	concentrations	
TA B L E  1  Noncompartmental	pharmacokinetic	parameters
 
Sultiame 
50 mg (n = 4)
Sultiame 
100 mg 
(n = 4)
Sultiame 
200 mg 
(n = 4)
Plasma	parameters
Cmax	(µg/mL) 0.02	(16) 0.18	(44) 1.88	(24)
Median	tmax	(h)	
(range)
7.0	(2.0-10.0) 2.0	(2.0-6.1) 1.5	(1.0-2.0)
AUC(0-inf) 
(µg·h	mL−1)
1.24	(63) 8.57	(33) 24.04	(27)
t1/2	(h) 50.8	(62) 90.9	(19) 40	(31)
CL/F	(L/h) 40.4	(93) 11.7	(25) 8.3	(26)
V/F	(L) 2964	(21) 1529	(21) 480	(26)
Whole blood parameters
Cmax	(µg/mL) 7.91	(17) 15.87	(19) 17.19	(17)
Median	tmax	(h)	
(range)
3.0	(2.0-8.0) 5.01	(5.0-6.0) 2.5	(1.0-3.0)
AUC(0-inf) 
(µg·h	mL−1)
3323	(44) 4535	(39) 4527	(43)
t1/2	(h) 313	(23) 233	(16) 253	(21)
CL/F	(L/h) 0.015	(37) 0.008	(34) 0.044	(41)
V/F	(L) 6.8	(21) 7.4	(21) 16.2	(27)
Urine	parameters
Recovery 
unchanged	(%)
1.61	(17) 5.24	(111) 16.73	(36)
Renal clearance 
(L/h)
0.17	(30) 0.14	(49) 0.13	(24)
Note: Geometric	means	(CV%)	of	noncompartmental	plasma	and	whole	
blood	PK	parameters	of	sultiame	after	administration	of	single	doses	of	
50,	100,	and	200	mg.
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are	available	in	Supplemental	material	along	with	goodness-of-fit	
plots,	normalized	prediction	error	(NPDE),	and	results	of	pcVPC.
3.4 | In vitro experiments
The	concentration-time	profiles	describing	sultiame	influx	into	erythro-
cytes	at	different	concentrations	are	shown	in	Figure	3.	Sultiame	was	
taken up almost instantaneously into the erythrocytes and the eryth-
rocyte/plasma ratio reached a steady state after about 10 minutes. 
This erythrocyte/plasma ratio decreased from 800 at concentrations 
of	10	mg/L	or	less,	to	less	than	30	for	concentrations	of	20	mg/L	and	
above. These results indicate that the saturation of erythrocytes oc-
curs	around	or	slightly	above	20	mg/L	(of	whole	blood	concentration).	
At	higher	concentrations,	the	excess	of	sultiame	increasingly	distributes	
between	 the	plasma	and	 the	erythrocytes	 (Figure	4).	Decreasing	 the	
experiment	temperature	slowed	down	the	rate	of	entry	of	sultiame	into	
the	cells,	without	significantly	modifying	the	erythrocyte/plasma	ratios.	
It allowed the estimation of kon and koff using a similar ligand to receptor 
model	at	4°C	where	the	rate	of	entry	was	observable.	Values	at	37°C	
could	be	deduced	using	Arrhenius’	law	(Figure	5)	and	were,	respectively,	
of	2018	µM−1 h−1	and	175	h−1.	The	efflux	experiments	revealed	the	re-
lease of only minute amounts of sultiame from incubated erythrocytes 
into	blank	plasma	(data	not	shown).	Eventually,	competition	studies	indi-
cated	that	sultiame's	affinity	for	erythrocytes	is	significantly	higher	than	
zonisamide's	and	topiramate's,	both	molecules	having	limited	capacity	
to	displace	sultiame	from	its	erythrocyte	binding	sites.	Conversely,	add-
ing	sultiame	to	a	sample	enriched	with	zonisamide	led	to	a	clear	efflux	
of	zonisamide	from	erythrocytes,	translating	into	an	increase	in	plasma	
level.	On	the	other	hand,	topiramate	did	not	really	display	affinity	for	
erythrocytes,	with	 an	 erythrocyte/plasma	 ratio	 close	 to	1,	 not	 influ-
enced	by	the	addition	of	sultiame	(data	not	shown).
4  | DISCUSSION
To	our	 knowledge,	our	preliminary	 clinical	PK	 study	 is	 the	 first	 to	
provide	a	detailed	description	of	sultiame's	PK	characteristics,	since	
the patenting of this antiepileptic agent in 1955 and its commerciali-
zation	 in	1960.9	The	PK	results	obtained	after	single	oral	adminis-
trations	of	50,	100,	and	200	mg	in	four	healthy	volunteers	showed	
striking	nonlinear	disposition	of	sultiame,	with	a	10-fold	increase	in	
Cmax	 for	each	doubling	of	dose.	Erythrocyte/plasma	concentration	
ratio	 further	 confirms	 sultiame's	 strong	 affinity	 for	 erythrocytes.	
The noticeable decrease in this ratio along escalating dosages indi-
cates saturable binding. This nonlinearity is likely to result from the 
strong	affinity	of	sultiame	for	CA	abundant	in	erythrocytes.
Indeed,	our	in	vitro	spiking	experiments	confirm	that	sultiame's	dis-
tribution	into	erythrocytes	occurs	quickly,	with	a	threshold	for	satura-
tion	reached	at	whole	blood	concentrations	of	about	20	mg/L.	Limited	
efflux	was	observed,	confirming	a	strong	affinity;	yet	a	covalent	binding	
of	sultiame	to	intracellular	CA	is	uncertain,	considering	that	a	dissocia-
tion rate constant (kD)	of	4.5	µM	could	be	estimated	in	vitro.
15,16	A	value	
comparable to the estimated kD of our final model (koff/kon	=	4	µM).	
Competition studies indicated that sultiame had a stronger affinity for 
erythrocytes	 than	 zonisamide.	Clinically,	 this	 suggests	 that	 displace-
ment of sultiame from the erythrocytes compartment is unlikely to 
occur	with	topiramate	or	zonisamide,	while	sultiame	addition	may	lead	
to	an	at	least	transient	increase	in	free	zonisamide,	with	a	potential	risk	
of	increased	effects	or	toxicity.	Fluctuations	in	the	plasma/erythrocyte	
ratio might also be associated with variations in efficacy when sultiame 
is	given	as	an	add-on	antiepileptic	drug	in	clinical	practice.
Using	 noncompartmental	 approaches,	 plasma	 and	 especially	
whole blood t1/2 appeared to be markedly longer than previously 
reported.6-8	 The	 range	 2-16	 hours	 currently	 reported	 in	 the	man-
ufacturer's	 information	 might	 have	 resulted	 from	 difficulties	 to	
TA B L E  2  Final	population	compartmental	model	parameters
Parameter
Population pharmacokinetics analysis Bootstrap evaluation
Estimate RSE(%) BSV(%) RSE (%) Median CI95% BSV(%) CI95%
CLplasma	(L/h) 9.95 11.8 28.8 15 9.95 (8.4;11.8) 27 (0.5;42)
Vc	(L) 64.8 18.1 – – 64.8 (52.1;80.6) – –
Very	(L) 3.27 7 – – 3.27 (2.8;3.6) – –
ka (h
−1) 1.88 13.8 – – 1.88 (1.3;2.1) – –
kon (h
−1·µM−1) 2018 – – – 2018 – – –
koff (h
−1) 8080 19.2 – – 8080 (6626;11209) – –
Btot	(mg) 111 2.1 – – 111 (105;117) – –
QRen	(%) 28.8 13 24.3 67.6 28.8 (22.9;37.4) 24 (0.8;33)
σprop,c	(CV%) 0.426 9 – – 0.424 (0.38;0.45) – –
σprop,ery	(CV%) 0.3 11 – – 0.299 (0.21;0.32) – –
σprop,urine	(CV%) 0.39 34 – – 0.39 (0.24;0.49) – –
Abbreviations:	BSV,	Between-subject	variability;	Btot,	ligand	maximal	binding	capacity;	CI95%,	95%	confidence	interval;	CLplasma,	plasma	clearance;	
ka,	constant	of	absorption;	koff,	dissociation	constant;	kon,	association	constant,	not	estimated	but	fixed	to	2018	h
−1	µM-1;	QRen,	fraction	eliminated	
by	renal	route;	RSE,	Relative	standard	error	of	the	estimate,	defined	as	SE(estimate)/estimate,	expressed	as	a	percentage,	with	SE(estimate)	retrieved	
directly	from	the	NONMEM	output	file;	Vc,	central	volume	of	distribution;	Very,	cell	volume	of	distribution;	σprop,	exponential	residual	error	on	plasma	
(p),	erythrocytes	(ery),	and	urine.
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determine low sultiame concentrations with analytical methods 
available	in	the	past.	Considering	whole	blood,	we	observed	t1/2 val-
ues	of	up	 to	13	days.	As	 the	 terminal	plasma	 t1/2 is dependent of 
erythrocytes affinity for sultiame and limited by its dissociation from 
its	binding	site	in	erythrocytes,	our	compartmental	model	predicts	
that plasma concentration curves should display a terminal t1/2 not 
different	 from	whole	 blood.	 However,	 plasma	 concentrations	 fol-
lowed up during this terminal phase fall were close to the limit of 
quantification	of	method,	hence	the	shorter	apparent	t1/2 observed 
in	our	plasma	values.	Further	studies	involving	the	repeated	admin-
istrations	of	daily	doses	might	allow	a	better	characterization	of	the	
terminal phase of plasma concentrations after treatment interrup-
tion. Still an important accumulation of sultiame during long term is 
not	expected	despite	this	presumably	long	t1/2,	due	to	the	saturable	
aspect	of	the	uptake	by	the	receptor-rich	intracellular	compartment.
The distribution volume corresponding to whole blood ranges 
from	 6.8	 to	 16.2	 L	 according	 to	 noncompartmental	 calculations,	
while	it	is	much	larger	with	respect	to	plasma,	in	line	with	sultiame	
distribution	outside	of	the	plasma	compartment,	into	erythrocytes	
and	others	tissues	containing	CA.	Plasma	and	whole	blood	noncom-
partmental	V/F	 and	CL/F	 estimates	 reveal	 as	well	 a	 striking	 dose	
dependency,	 consistent	with	 the	saturable	aspect	of	 sultiame	dis-
tribution. Our compartmental model does not indicate that sultiame 
CL/F	 from	 the	 central	 plasma	 compartment	would	have	 any	non-
linear	aspect.	 In	 terms	of	urinary	excretion,	a	constant	renal	CL/F	
(range:	0.13-0.17	L/h)	 is	 actually	observed,	 despite	 the	nonlinear-
ity	 in	 urinary	 recovery	 of	 unchanged	 sultiame,	 again	 consequent	
to saturable intracellular uptake. The fraction eliminated by renal 
route	 is	 28.8%,	 as	 already	 described	 in	 the	 summary	 of	 product	
characteristics.8
F I G U R E  3   Concentrations of sultiame 
in	plasma	(A)	and	in	erythrocytes	(B)	
along incubation time during in vitro 
spiking	experiments	at	37°C	and	with	
target	concentrations	of	1	mg/L	(light	
grey),	5	mg/L	(dark	grey),	10	mg/L	(black),	
20	mg/L	(dashed	line),	40	mg/L	(dotted	
line),	and	80	mg/L	(dashed-dotted	line)
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A	two-compartment	model	fitted	by	nonlinear	mixed-effect	re-
gression	was	able	to	describe	adequately	our	plasma,	erythrocytes	
PK	observations	with	an	additional	compartment	for	urine	data,	as-
suming a nonlinear distribution and a linear elimination of sultiame. 
A	ligand	to	receptor	saturation	model	fitted	remarkably	well	with	the	
hypothesized	binding	of	sultiame	to	erythrocytes,	supposedly	onto	
CA	abundant	in	these	cells,	but	also	present	in	other	tissues	including	
brain.	The	plasma	CL/F	of	10.0	L/h	estimated	with	this	model	is	of	
the same order of magnitude of values calculated with noncompart-
mental	 formulas.	Volumes	of	distribution	of	64.8	L	for	plasma	and	
3.3	L	were	estimated	for	the	erythrocyte	compartment.	As	already	
mentioned,	the	erythrocyte	compartment	must	be	considered	to	en-
compass	as	well	other	tissues	containing	CA	able	to	bind	sultiame.	
Yet	its	volume	only	moderately	exceeds	the	2	L	or	so	corresponding	
to	 the	 total	erythrocytes	mass	of	normal	adults,17 which indicates 
that	erythrocytes	actually	contain	the	largest	part	of	CA	able	to	bind	
sultiame	in	the	organism.	A	maximal	binding	capacity	of	111	mg	was	
estimated,	corroborating	the	saturation	of	distribution	observed	in	
vivo for doses of 100 mg and above (see concentrations in eryth-
rocytes	 in	 Figure	 2).	 This	 estimate	 is	 consistent	 with	 our	 in	 vitro	
evaluation	of	a	binding	capacity	slightly	exceeding	20	mg	per	 liter	
of	whole	blood,	considering	that	the	normal	volume	of	whole	blood	
amounts	to	4.5-5	L.	A	ligand	to	receptor	saturation	model	actually	
fitted our data better than the nonlinear disposition models found in 
the	literature	that	used	a	sigmoid	Bmax	equation	to	account	for	non-
linearity.11,18	A	ligand	to	receptor	model,	where	the	ratio	of	kon/koff 
F I G U R E  4   In vitro concentrations of 
sultiame in erythrocytes versus plasma: 
values	at	equilibrium	(after	60	minutes	
of	incubation)	are	represented	for	
each	spiking	experiments.	Open	circles	
represent the spiked concentration of 
sultiame with the corresponding plasma 
and erythrocyte concentrations
F I G U R E  5   In	vitro	concentrations	of	sultiame	in	erythrocytes	and	plasma	at	different	temperatures,	values	of	concentrations	at,	
respectively,	4°C,	21°C,	and	37°C	are	represented	along	incubation	time	(with	a	concentration	of	20	mg/L).	Observed	erythrocyte	
concentrations	(open	circles),	observed	plasma	concentrations	(black	circles),	and	predicted	concentration	profiles	(continuous	lines)	are	
represented.	Estimates	of	kon and koff for each temperature derived from the model are represented in the table below
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accounts for the dissociation constant kD found at the denominator 
the	Bmax	sigmoid	equation,	probably	describes	more	accurately	the	
disposition	of	sultiame	before	steady-state	conditions	are	reached.
As	our	population	model	is	based	on	a	limited	amount	of	data,	be-
tween subject variability and estimation of errors are evaluated with 
poor	precision,	as	indicated	by	their	wide	standard	error	and	CI95%.
Globally,	our	results	have	mainly	an	orientation	value	and	should	
essentially	serve	to	design	further	clinical	studies	with	sultiame,	par-
ticularly in the pediatric population as part of therapy of benign child-
hood epilepsy with centrotemporal spikes.3 They should also be taken 
into	consideration	to	elaborate	an	adequate	framework	of	interpreta-
tion for the therapeutic monitoring of sultiame circulating concentra-
tions,	not	only	in	plasma	but	also	in	whole	blood,	which	might	present	
a clinical interest as for other recent antiepileptic agents.19
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